Biogen Pays Elan $3.25 Billion to Take Over MS Drug

06.02.2013 - Biogen is to take full ownership of blockbuster multiple sclerosis drug Tysabri after agreeing to pay Irish partner Elan $3.25 billion plus future royalties on sales of the drug...